Radioimmunotherapy with anti-CD66 antibody labelled with 90Y for myeloablation prior to stem cell transplantation reloaded


The doctors and researchers at the University Hospital of Ulm from the Departments of Hemato-Oncology and Nuclear medicine have successfully re-started their programme for Radioimmunotherapy (RIT) under the §13.2b of AMG. The RIT with 90Y (beta particle emitter) labelled anti-CD66 antibody offers a unique advantage of delivering very high radiation to the bone marrow for myeloablation prior to stem cell transplantation of hematological malignancies e.g. myelodysplastic syndrome and acute myeloid leukemia. The initial experience in patients has been extremely encouraging.




Figure 1: An MDS Patient‘s dosimetry image (posterior view) acquired at 24 hrs after injection of 99mTc-labelled anti-CD66 antibody showing intense uptake in the bone marrow (A). The Bremsstrahlung image (posterior view) acquired at 24 hrs after RIT with 90Y-labelled anti-CD66 antibody confirmed high uptake of the radiolabelled antibody in the bone marrow (B). Faint tracer uptake is also seen in the liver and spleen whereas the kidney does not show any relevant uptake. Dosimetry based on PBPK modelling correctly predicted the dose delivered to the bone marrow.




For further information please contact:

Nuclear Medicine

  • Profilbild von Prof. Dr. Ambros J. Beer

    Prof. Dr. Ambros J. Beer

    Ärztlicher Direktor der Klinik für Nuklearmedizin

  • Profilbild von Dr. med. Nina Eberhardt

    Dr. med. Nina Eberhardt

    Leitende Oberärztin (komm.), FÄ Nuklearmedizin



Or you can contact the secretary's office of the
Clinic for Nuclear Medicine


Hematology Oncology